Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial.

Santeri A Pakola Katriina J Peltola James H A Clubb Elise Jirovec Lyna Haybout Tatiana Viktorovna Kudling Tuomo Alanko Riitta Korpisaari Susanna M Juteau Marjut Laukka Jorma Sormunen Jukka Kemppainen Annabrita Hemmes Teijo Pellinen Mirte van der Heijden Dafne C A Quixabeira Claudia Kistler Suvi Sorsa Riikka Havunen Joao M Santos Victor Cervera-Carrascon Akseli E Hemminki

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

TILT-123 was safe and able to produce antitumor effects in local and distant lesions in heavily pre-treated patients. Good tolerability of TILT-123 facilitates combination studies, several of which are ongoing (NCT04217473, NCT05271318, NCT05222932, and NCT06125197). See related commentary by Silva-Pilipich and Smerdou, p. 3649.

Keyphrases

end stage renal disease
newly diagnosed
open label
ejection fraction
chronic kidney disease
clinical trial
prognostic factors
lymph node
randomized controlled trial
phase ii
patient reported outcomes
phase iii
combination therapy
machine learning
big data
young adults
drug induced
childhood cancer